company background image
4593 logo

Healios K.K TSE:4593 Stock Report

Last Price

JP¥181.00

Market Cap

JP¥16.2b

7D

0.6%

1Y

9.0%

Updated

12 Dec, 2024

Data

Company Financials +

Healios K.K. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Healios K.K
Historical stock prices
Current Share PriceJP¥181.00
52 Week HighJP¥264.00
52 Week LowJP¥114.00
Beta0.92
1 Month Change-10.40%
3 Month Change-17.35%
1 Year Change9.04%
3 Year Change-86.12%
5 Year Change-87.53%
Change since IPO-89.28%

Recent News & Updates

Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Dec 05
Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Recent updates

Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Dec 05
Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Is Healios K.K (TSE:4593) Using Too Much Debt?

May 31
Is Healios K.K (TSE:4593) Using Too Much Debt?

Shareholder Returns

4593JP BiotechsJP Market
7D0.6%-4.3%0.3%
1Y9.0%23.2%14.6%

Return vs Industry: 4593 underperformed the JP Biotechs industry which returned 23.2% over the past year.

Return vs Market: 4593 underperformed the JP Market which returned 14.6% over the past year.

Price Volatility

Is 4593's price volatile compared to industry and market?
4593 volatility
4593 Average Weekly Movement6.5%
Biotechs Industry Average Movement7.2%
Market Average Movement3.7%
10% most volatile stocks in JP Market7.4%
10% least volatile stocks in JP Market1.9%

Stable Share Price: 4593's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: 4593's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
201164Hardy Kagimotowww.healios.co.jp

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.

Healios K.K. Fundamentals Summary

How do Healios K.K's earnings and revenue compare to its market cap?
4593 fundamental statistics
Market capJP¥16.22b
Earnings (TTM)-JP¥6.22b
Revenue (TTM)JP¥549.00m

29.7x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4593 income statement (TTM)
RevenueJP¥549.00m
Cost of RevenueJP¥98.00m
Gross ProfitJP¥451.00m
Other ExpensesJP¥6.67b
Earnings-JP¥6.22b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)-69.03
Gross Margin82.15%
Net Profit Margin-1,133.33%
Debt/Equity Ratio117.8%

How did 4593 perform over the long term?

See historical performance and comparison